arrow
S

Shi Zhao

Tianjin Medical University
H指数:45
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical severity and co-infection of respiratory pathogens among children and adolescents with Mycoplasma pneumoniae infection in Guangzhou, China: a single-center retrospective cohort study

广州地区儿童和青少年支原体肺炎感染的临床严重程度及呼吸道病原体共感染情况:一项单中心回顾性队列研究

2026-09-050
OA
Real-world evaluation of Chinese National Maternal and Newborn Safety Action Plan for reducing neonatal mortality among pregnant women with conditions: a retrospective, matched, population-based cohort study

对中国国家母婴安全行动计划在降低合并症孕产妇新生儿死亡率中的实际效果评估:一项回顾性、匹配、基于人群的队列研究

2026-02-010
PRE
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study

尼马曲韦/利托那韦和莫那比拉韦在降低新型冠状病毒肺炎短期和长期心血管并发症风险方面的有效性: 一项目标试验仿真研究

2025-12-210
OAAI
Risk of HIV viral rebound after SARS-CoV-2 infection among people living with HIV on antiretroviral therapy: a retrospective matched cohort study

接受抗逆转录病毒治疗的HIV感染者中,SARS-CoV-2感染后HIV病毒反弹的风险:一项回顾性匹配队列研究

2025-12-010
PRE
Associations of PM2.5 Carbonaceous and Ionic Constituents with Fractional Exhaled Nitric Oxide (FeNO): A Panel Study with 16 Follow-up Visits over 4 years

PM2.5碳质和离子组分与呼出气一氧化氮(FeNO)的关联性:一项为期4年、包含16次随访访问的队列研究

2025-11-190
PRE
Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study

Nirmatrelvir-ritonavir立即开始治疗对COVID后结果的更大益处: 一项基于人群的回顾性队列研究

2025-11-100
OAAI
SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study

新型冠状病毒肺炎患者的SARS-CoV-2反弹和急性后死亡率和住院: 队列研究

2025-07-280
OAAI
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation

nirmatrelvir/ritonavir和molnupiravir对门诊患者的post-COVID-19结果的有效性: 目标试验仿真研究

2025-02-180
OAAI